Research Calls I
-
Upgrades:
- Banc of California (BANC) upgraded to Overweight from Equal Weight at Barclays; tgt raised to $18
- Danaher (DHR) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $285
- Envista (NVST) upgraded to Market Perform from Underperform at Leerink Partners; tgt raised to $23
- KLA Corporation (KLAC) upgraded to Outperform from Perform at Oppenheimer; tgt raised to $850
- L3Harris (LHX) upgraded to Buy from Neutral at BofA Securities; tgt $300
- Meritage (MTH) upgraded to Buy from Neutral at Goldman; tgt raised to $235
- Omega Health (OHI) upgraded to Outperform from Neutral at Exane BNP Paribas; tgt $49
- Regions Fincl (RF) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $28
- Smurfit Westrock plc (SW) upgraded to Outperform from Sector Perform at RBC Capital Mkts; tgt raised to $58
- Valley National (VLY) upgraded to Equal Weight from Underweight at Barclays; tgt raised to $10
- Wingstop (WING) upgraded to Buy from Neutral at BTIG Research; tgt $370
-
Downgrades:
- Arm Holdings plc (ARM) downgraded to Underperform from Mkt Perform at Bernstein; tgt $100
- Biogen (BIIB) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt lowered to $204
- Blackbaud (BLKB) downgraded to Neutral from Outperform at Robert W. Baird; tgt lowered to $80
- Brinker (EAT) downgraded to Market Perform from Outperform at BMO Capital Markets; tgt raised to $105
- Brinker (EAT) downgraded to Neutral from Overweight at JP Morgan; tgt raised to $100
- FirstEnergy (FE) downgraded to Neutral from Buy at Seaport Research Partners
- First Interstate Bancsystem (FIBK) downgraded to Underweight from Equal Weight at Barclays; tgt lowered to $30
- GlaxoSmithKline (GSK) downgraded to Neutral from Buy at Guggenheim
- Kraft Heinz (KHC) downgraded to Hold from Buy at Deutsche Bank; tgt lowered to $35
- Option Care Health (OPCH) downgraded to Hold from Buy at Jefferies; tgt lowered to $26
- TE Connectivity (TEL) downgraded to Reduce from Hold at HSBC Securities; tgt $137
- Trane (TT) downgraded to Hold from Buy at HSBC Securities; tgt $405
-
Others:
- Alumis (ALMS) initiated with an Outperform at Robert W. Baird; tgt $25
- Enliven Therapeutics (ELVN) initiated with a Buy at JonesResearch
- ORIC Pharmaceuticals (ORIC) initiated with an Overweight at Wells Fargo; tgt $20
- ORIC Pharmaceuticals (ORIC) initiated with a Buy at JonesResearch
- Terns Pharmaceuticals (TERN) initiated with an Outperform at Oppenheimer; tgt $82
- Vanda Pharma (VNDA) initiated with a Buy at H.C. Wainwright; tgt $18